Effects of β-adrenoceptor antagonist and 5-HT1A and 5-HT1B receptor antagonist alprenolol on human Kv1.3 currents

Eunseo Kim1, Su-Hyun Jo1

  • 1Department of Physiology, Institute of Bioscience and Biotechnology, Kangwon National University College of Medicine, Chuncheon 24341, Korea.

Insights

Alprenolol, a cardiovascular drug, affects human Kv1.3 channel currents in a concentration-dependent manner, influencing T lymphocyte function. This study reveals biphasic effects on hKv1.3 channels, impacting immune responses.

Area of Science:

  • Pharmacology
  • Immunology
  • Ion Channel Physiology

Background:

  • Alprenolol is a nonselective β-adrenoceptor antagonist used for cardiovascular diseases.
  • Human Kv1.3 channels (hKv1.3) are crucial for T lymphocyte proliferation and activation.
  • The role of alprenolol on hKv1.3 channel function remains largely unexplored.

Purpose of the Study:

  • To investigate the acute effects of alprenolol on human Kv1.3 (hKv1.3) channel currents.
  • To determine if alprenolol modulates hKv1.3 channel biophysical properties.
  • To assess the potential impact of these modulations on immune cell function.

Main Methods:

  • Two-microelectrode voltage clamp recordings in *Xenopus* oocytes expressing hKv1.3 channels.
  • Application of varying concentrations of alprenolol (1–1,000 μM).
  • Analysis of current amplitudes, activation/inactivation kinetics, and voltage-dependence.

Main Results:

  • Alprenolol exhibited concentration-dependent biphasic effects: current potentiation at 1-100 μM and inhibition at 300-1,000 μM.
  • Significant alterations in peak and steady-state currents, inactivation time constants, and activation kinetics were observed.
  • A use-dependent blockade of hKv1.3 currents by alprenolol was identified at high concentrations.

Conclusions:

  • Alprenolol modulates hKv1.3 channel function through concentration-dependent biphasic effects and altered biophysical properties.
  • These modulations suggest that alprenolol can influence T lymphocyte activity via hKv1.3 channels.
  • Drug concentration and usage patterns may critically affect alprenolol's impact on immune function.

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
893
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
635
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.0K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
785
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
1.9K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K